“医美茅台”爱美客增长不动了吗？

作者：张从容文章来源：亿邦动力

2025-03-20 16:55

作者：张从容文章来源：亿邦动力

2025-03-20 16:55

邦小白快读

全文速览

爱美客2024年财务数据揭示显著增长放缓趋势。

1. 营业总收入达30.26亿元，同比增长仅5.45%，为近5年最低增长率，远低于2023年的45%以上、2022年的30%以上和2021年的100%以上。

2. 利润指标全面减速：营业利润22.91亿元增长6.13%，利润总额22.81亿元增长5.82%，净利润19.56亿元增长5.47%，归属于母公司股东的净利润19.58亿元增长5.33%，所有增长率均未超过7%。

3. 主营产品收入增长大幅回落：溶液类注射产品收入17.44亿元，同比增长4.4%，对比2023年的29.22%明显下降；凝胶类注射产品收入12.16亿元，同比增长5.01%，远低于2023年的81.43%。

4. 销售量数据同样疲软：溶液类注射产品销售量634.63万支，增长23.44%，是2020年至2024年增速最慢的一年；凝胶类注射产品销售量89.36万支，同比下降11.24%，显示需求减弱。

爱美客年报反映医美市场消费趋势与产品动态。

1. 消费趋势：整体收入增长放缓至5.45%，为近5年最低，提示医美消费需求可能趋于饱和或竞争加剧。

2. 产品研发：溶液类和凝胶类产品收入增长分别降至4.4%和5.01%，增速远低于往年，表明现有产品面临创新瓶颈，需关注研发升级。

3. 用户行为观察：溶液类销售量增长23.44%但增速最慢，凝胶类销售量下降11.24%，显示消费者偏好变化或市场饱和度提高，可指导品牌定位调整。

4. 品牌定价和价格竞争：增长率下降可能暗示价格敏感度增加，品牌需优化定价策略以应对市场挑战。

爱美客增长放缓提供市场风险与机会洞察。

1. 增长市场：收入增长率降至5.45%，为近5年最低，远低于历史水平，提示医美市场整体增速下降。

2. 风险提示：主营产品收入增长大幅减速（溶液类4.4%、凝胶类5.01%），且凝胶类销售量下降11.24%，显示需求萎缩风险，卖家需警惕库存积压。

3. 事件应对措施：无直接事件，但数据反映市场环境变化，可学习点包括监控销售数据和调整策略。

4. 机会提示：对比2023年高增长数据，当前增速虽低，但仍有增长空间，卖家可探索细分市场或合作方式以规避风险。

年报数据揭示产品生产需求与商业机会。

1. 产品生产和设计需求：溶液类注射产品销售量增长23.44%但增速最缓，凝胶类注射产品销售量下降11.24%，工厂需调整生产计划以适应需求变化。

2. 商业机会：市场增长放缓至5.45%，可能推动工厂探索新产品线或创新设计，如研发高需求品类。

3. 推进数字化和电商启示：销售量数据波动（如凝胶类下降11.24%）提示需加强数字化监控和电商渠道优化，以提升生产和响应效率。

行业发展趋势与客户痛点分析。

1. 行业发展趋势：爱美客收入增长放缓至5.45%，为近5年最低，反映医美行业整体增速下降趋势。

2. 客户痛点：溶液类和凝胶类产品收入增长大幅减速（分别至4.4%和5.01%），凝胶类销售量下降11.24%，显示客户面临需求不足和销售压力痛点。

3. 解决方案：无直接方案，但数据提示服务商可开发工具帮助客户监控市场变化和优化运营。

商业需求与平台风险规避启示。

1. 商业对平台需求和问题：增长放缓至5.45%，可能影响平台招商吸引力，如爱美客表现不佳提示入驻企业减少。

2. 平台招商和运营管理：产品收入增长减速（溶液类4.4%、凝胶类5.01%）和销售量变化（凝胶类下降11.24%）要求平台加强运营管理，优化招商策略。

3. 风险规避：增长率降至近5年最低，提示平台需规避增长放缓风向，如监控市场数据和调整政策。

产业新动向与新问题研究。

1. 产业新动向：爱美客收入增长放缓至5.45%，创近5年最低点，反映医美产业增速显著下降趋势。

2. 新问题：增长率从2021年的100%以上降至2024年的5%左右，产品收入增长大幅减速（如凝胶类从81.43%降至5.01%），销售量变化（凝胶类下降11.24%）引发研究问题如市场饱和原因。

3. 商业模式：年报数据提供现有商业模式表现，可分析高增长期（2021-2023）与当前低增长期的差异，为政策法规建议提供基础。

声明：快读内容全程由AI生成，请注意甄别信息。如您发现问题，请发送邮件至 run@ebrun.com 。

我是品牌商卖家工厂服务商平台商研究者帮我再读一遍。

Quick Summary

Imeik's 2024 financial data reveals a significant growth slowdown.

1. Total operating revenue reached RMB 30.26 billion, with a year-on-year growth of only 5.45%, the lowest growth rate in the past five years. This is far below the over 45% growth in 2023, over 30% in 2022, and over 100% in 2021.

2. All profit indicators decelerated: operating profit grew 6.13% to RMB 22.91 billion, total profit grew 5.82% to RMB 22.81 billion, net profit grew 5.47% to RMB 19.56 billion, and net profit attributable to shareholders of the parent company grew 5.33% to RMB 19.58 billion. None of the growth rates exceeded 7%.

3. Revenue growth from core products declined sharply: revenue from solution-based injectable products was RMB 17.44 billion, up 4.4% YoY, a significant drop from 29.22% in 2023; revenue from gel-based injectable products was RMB 12.16 billion, up 5.01% YoY, far below the 81.43% growth in 2023.

4. Sales volume data also showed weakness: sales volume of solution-based injectable products grew 23.44% to 6.3463 million units, the slowest growth rate from 2020 to 2024; sales volume of gel-based injectable products fell 11.24% YoY to 893,600 units, indicating weakening demand.

Imeik's annual report reflects consumption trends and product dynamics in the medical aesthetics market.

1. Consumption Trend: Overall revenue growth slowed to 5.45%, the lowest in five years, suggesting potential market saturation or intensified competition in medical aesthetics consumption.

2. Product R&D: Revenue growth for solution-based and gel-based products decelerated to 4.4% and 5.01% respectively, significantly lower than previous years, indicating innovation bottlenecks for existing products and highlighting the need for R&D upgrades.

3. User Behavior Observation: Solution-based product sales volume grew 23.44% but at the slowest pace, while gel-based product sales volume declined 11.24%, signaling shifting consumer preferences or increased market saturation, which can guide brand positioning adjustments.

4. Pricing and Competition: The growth slowdown may imply rising price sensitivity, necessitating optimized pricing strategies to address market challenges.

Imeik's growth slowdown offers insights into market risks and opportunities.

1. Growth Market: Revenue growth dropped to 5.45%, the lowest in five years and significantly below historical levels, indicating a broader slowdown in the medical aesthetics market.

2. Risk Alert: Core product revenue growth decelerated sharply (4.4% for solution-based, 5.01% for gel-based), with gel-based product sales volume falling 11.24%, pointing to demand contraction risks. Sellers should be cautious of inventory buildup.

3. Response Measures: While no direct event occurred, the data reflects changing market conditions. Key takeaways include closely monitoring sales data and adjusting strategies accordingly.

4. Opportunity Insight: Despite the low current growth rate compared to 2023's high growth, there remains growth potential. Sellers can explore niche markets or partnerships to mitigate risks.

The annual report data reveals production demand shifts and commercial opportunities.

1. Production and Design Needs: Sales volume of solution-based injectable products grew 23.44% but at the slowest rate, while gel-based injectable product sales volume fell 11.24%. Factories need to adjust production plans to adapt to changing demand.

2. Commercial Opportunities: Market growth slowing to 5.45% may drive factories to explore new product lines or innovative designs, such as developing high-demand categories.

3. Digital and E-commerce Implications: Fluctuating sales volume data (e.g., gel-based products down 11.24%) highlights the need for enhanced digital monitoring and e-commerce channel optimization to improve production and response efficiency.

Analysis of industry development trends and client pain points.

1. Industry Trend: Imeik's revenue growth slowed to 5.45%, the lowest in five years, reflecting a broader deceleration trend in the medical aesthetics industry.

2. Client Pain Points: Sharp revenue growth deceleration for solution-based and gel-based products (to 4.4% and 5.01% respectively), coupled with an 11.24% decline in gel-based product sales volume, indicates clients face challenges with insufficient demand and sales pressure.

3. Solution Direction: While no direct solution is provided, the data suggests service providers can develop tools to help clients monitor market changes and optimize operations.

Insights into commercial demands and platform risk mitigation.

1. Platform Demand and Issues: Growth slowing to 5.45% may impact the platform's appeal to merchants, as poor performance from key players like Imeik could signal reduced enterprise participation.

2. Merchant Recruitment and Operations Management: Decelerating product revenue growth (4.4% for solution-based, 5.01% for gel-based) and sales volume changes (gel-based down 11.24%) require platforms to strengthen operational management and optimize merchant recruitment strategies.

3. Risk Mitigation: The growth rate falling to a five-year low signals the need for platforms to mitigate slowdown risks by monitoring market data and adjusting policies.

Research on new industry trends and emerging questions.

1. Industry Trend: Imeik's revenue growth slowed to 5.45%, hitting a five-year low, reflecting a significant deceleration trend in the medical aesthetics industry.

2. Research Questions: The growth rate plummeting from over 100% in 2021 to around 5% in 2024, coupled with sharp revenue growth deceleration for products (e.g., gel-based dropping from 81.43% to 5.01%) and sales volume changes (gel-based down 11.24%), raises research questions such as causes of market saturation.

3. Business Model Analysis: The annual report data provides performance metrics for the current business model, enabling analysis of differences between the high-growth period (2021-2023) and the current low-growth phase, forming a basis for policy and regulatory recommendations.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】3月19日，爱美客发布2024年年报。年报显示，爱美客2024年营业总收入30.26亿元，同比增长5.45%；营业利润22.91亿元，同比增长6.13%；利润总额22.81亿元，同比增长5.82%；净利润19.56亿元，同比增长5.47%；归属于母公司股东的净利润19.58亿元，同比增长5.33%。

值得注意的是，2024年爱美客的收入和利润增长均有所放缓，同比增长率均未超过7%，降至近5年最低；而在2023年，增长率均在45%以上，2022年为30%以上，2021年更是达到了惊人的100%以上。

其中，主营产品收入增长大幅减速。2024年，爱美客旗下溶液类注射产品营业收入17.44亿元，同比增长4.4%，2023年同比增长29.22%；凝胶类注射产品营业收入12.16亿元，同比增长5.01%，2023年同比增长81.43%。

溶液类注射产品的销售量增长同步放缓。2024年，爱美客溶液类注射产品销售量634.63万支，同比增长23.44%，是2020年至2024年中增速最慢的一年；凝胶类注射产品销售量89.36万支，同比下降11.24%。

亿邦持续追踪报道该情报，如想了解更多与本文相关信息，请扫码关注作者微信。

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可，任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题，烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com，我们将及时沟通与处理。

已点赞

好文章,值得被更多人看到

FAQ回顾

爱美客2024年主要财务数据是多少？

爱美客2024年营业总收入30.26亿元，同比增长5.45%；净利润19.56亿元，同比增长5.47%；归属于母公司股东的净利润19.58亿元，同比增长5.33%。

爱美客2024年主营产品表现如何？

溶液类注射产品营收17.44亿元，同比增长4.4%；凝胶类注射产品营收12.16亿元，同比增长5.01%。凝胶类产品销售量89.36万支，同比下降11.24%。

爱美客近年增长率变化趋势是什么？

2024年增长率降至5%左右，为近5年最低；2023年增长率在45%以上，2022年为30%以上，2021年达到100%以上，呈现明显放缓趋势。

标签:: 化妆品医疗未来零售

找“平替”找出65万粉丝小红书迎来“素人潮”？

具体来看，登上2月涨粉榜榜首的是@彩条屋影业（哪吒2热映中），单月涨粉64.75W。

未来零售电商平台内容电商种草

2025-03-20 16:29:53